Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
BörsenkürzelAMRX
Name des UnternehmensAmneal Pharmaceuticals Inc
IPO-datumNov 18, 2009
CEOMr. Chintu Patel
Anzahl der mitarbeiter8100
WertpapierartOrdinary Share
GeschäftsjahresendeNov 18
Addresse400 Crossing Boulevard, 3rd Floor
StadtBRIDGEWATER
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl08807
Telefon19089473120
Websitehttps://amneal.com/
BörsenkürzelAMRX
IPO-datumNov 18, 2009
CEOMr. Chintu Patel
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten